DXCM - FDA Approves Dexcom's Stelo As First Glucose Monitoring Device Without Prescription | Benzinga
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM).
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for anyone 18 years and older who does not use insulin.
The company said Stelo will be available online without a prescription starting summer of 2024.
This system is not for individuals with problematic hypoglycemia (low blood sugar) as the system is not designed to alert the user to this potentially dangerous condition.
The Stelo ...